Core Viewpoint - The article discusses the rise of Qi Yijia, the founder of Brain Regeneration Technology, who topped the "2026 Hurun Global Rich List" with a wealth of 91 billion RMB, highlighting the company's focus on traditional Chinese medicine for neurocognitive disorders despite its history of losses and lack of product sales [4][6]. Group 1: Company Overview - Brain Regeneration Technology specializes in the research and commercialization of traditional Chinese medicine targeting neurocognitive disorders and degenerative diseases, particularly ADHD and ASD [7][11]. - The company has not generated any product sales revenue since its establishment in 2014, accumulating a net loss of approximately 24 million USD over seven years [4][9]. - As of June 30, 2025, the company reported a net loss of 3.58 million USD for the fiscal year, with total operating expenses of 3.77 million USD, primarily due to administrative costs [9][10]. Group 2: Financial Performance - The company's stock price experienced significant volatility, peaking at 60 USD per share, leading to a market capitalization of approximately 29.67 billion USD before falling to around 12.81 billion USD [6][9]. - Despite the high valuation, the company has consistently operated at a loss, with the latest financial reports indicating a continued lack of revenue generation [9][10]. Group 3: Leadership and Ownership - Qi Yijia holds 88.6% of the company's shares, making it a family-run business, with his brother also involved in the executive team [11]. - The company has a unique governance structure, with the founder's father, a renowned traditional Chinese medicine practitioner, contributing to the development of the company's core products [11][12]. Group 4: Market Position and Future Prospects - The surge in Qi Yijia's wealth is attributed to the popularity of brain-computer interface technology, which the company is attempting to leverage for its product development [5][6]. - The future of Brain Regeneration Technology hinges on its ability to commercialize its research and generate revenue, particularly in the context of its focus on ADHD and ASD treatments [18].